GREENLAND MINES LTD Net Income (Loss) Available to Common Stockholders, Diluted
GREENLAND MINES LTD (GRML) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$123.22 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-23.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-05-23
- GREENLAND MINES LTD net income (loss) available to common stockholders, diluted for the quarter ending 2024-03-31 was -$123.22K, a 111.00% decline year-over-year.
- GREENLAND MINES LTD net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$153.55K.
- GREENLAND MINES LTD net income (loss) available to common stockholders, diluted for the quarter ending 2023-03-31 was $1.12M.
- GREENLAND MINES LTD net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was $716.07K.
- GREENLAND MINES LTD net income (loss) available to common stockholders, diluted for fiscal 2023 was $1.35M, a 9.14% increase from fiscal 2022.
- GREENLAND MINES LTD net income (loss) available to common stockholders, diluted for fiscal 2022 was $1.23M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 10 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | -$123.22K 10-Q · filed 2024-05-23 | ||||
| 2023-12-31 | $1.35M 10-K · filed 2024-04-17 | ||||
| 2023-06-30 | -$153.55K 10-Q · filed 2023-08-21 | $967.07K 10-Q · filed 2023-08-21 | $1.68M derived: sum of 3 quarters · filed 2024-05-23 | $2.41M derived: sum of 4 quarters · filed 2024-05-23 | |
| 2023-03-31 | $1.12M 10-Q · filed 2024-05-23 | $1.84M derived: sum of 2 quarters · filed 2024-05-23 | $2.57M derived: sum of 3 quarters · filed 2024-05-23 | $2.36M derived: sum of 4 quarters · filed 2024-05-23 | |
| 2022-12-31 | $716.07K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | $1.45M derived: sum of 2 quarters · filed 2024-04-17 | $1.24M derived: sum of 3 quarters · filed 2024-04-17 | $1.23M 10-K · filed 2024-04-17 | |
| 2022-09-30 | $731.12K 10-Q · filed 2022-11-14 | $522.29K derived: sum of 2 quarters · filed 2023-08-21 | $517.29K 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | -$208.83K 10-Q · filed 2023-08-21 | -$213.84K 10-Q · filed 2023-08-21 | |||
| 2022-03-31 | -$5.01K 10-Q · filed 2023-05-24 | ||||
| 2021-12-31 | -$3.56K 10-K/A · filed 2023-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |